United States Immunohistochemistry Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Global Immunohistochemistry Market size was valued at US$ 2,302.79 million in 2022 and is estimated to reach US$4,240.65 million by 2031, growing at a CAGR of 8.1% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/immunohistochemistry-market?sb

Key Development:

United States: Recent Industry Developments

✅ In February 2026, the U.S. Food and Drug Administration approved PD‐L1 IHC 22C3 pharmDx as an FDA‐cleared immunohistochemistry companion diagnostic to aid identification of patients with multiple cancer types who may benefit from targeted immunotherapy, enhancing precision oncology workflows.

✅ In February 2026, Indica Labs expanded its AI‐assisted pathology portfolio with enhancements to its HALO platform aimed at improved molecular testing in breast cancer, enabling more automated and data‐driven immunohistochemistry interpretation.

✅ In February 2026, researchers introduced iSight, a multi‐task AI framework trained on millions of IHC images to automate staining assessment and improve interpretation accuracy for complex tissue specimens, signaling a major computational advance in IHC analysis.

✅ In December 2025, scientific teams developed a cross‐stain contrastive learning model to improve joint representation of immunohistochemistry and histopathology slides, boosting analytical depth and aiding cancer subtype classification in computational pathology research.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=immunohistochemistry-market

Japan: Recent Industry Developments

✅ In February 2026, Japanese and global researchers presented progressive AI‐driven computational methods for translating standard histology slides into IHC‐equivalent images with enhanced structural fidelity, aiming to streamline and augment routine diagnostic staining interpretation.

✅ In February 2026, the Japan Foundation of Cancer Research and NEC confirmed collaborative research into advanced cancer vaccine targets using whole‐genome data, setting the stage for future integration of IHC biomarkers with next‐generation immune oncology research in Japan.

✅ In December 2025, Sysmex Corporation launched expanded immunoassay panels (including aldosterone and renin assay kits) in Japan to broaden diagnostic capabilities, indirectly supporting enhanced tissue diagnostic workflows that can interface with immunohistochemistry in endocrinology and pathology labs.

✅ In November 2025, Asia‐Pacific diagnostic firms including Roche Diagnostics began rolling out new antibody panels for clinical use in Japan and neighboring markets to support IHC‐based cancer diagnostics, expanding assay toolkits for Japanese pathology labs.

Key Players:

=> Danaher Corporation, F. Hoffmann-La Roche Ag., BD, Agilent Technologies, Inc., Merck Kgaa, Bio-Rad Laboratories, Inc., BioGenex, Abcam Plc, Candor Bioscience Gmbh and PerkinElmer, Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/immunohistochemistry-market?sb

Key Segments:

By Product

Antibodies account for 30% share, driven by increasing use in diagnostics, research, and therapeutic applications. Reagents hold 25%, widely used in laboratory assays and drug testing. Equipment represents 20%, including instruments for diagnostics and forensic applications. Kits cover 25%, reflecting growth in ready-to-use diagnostic and research kits for hospitals and labs.

By Application

Diagnostics dominate with 35% share, fueled by rising demand for rapid and accurate disease detection. Drug Testing represents 20%, supported by increasing regulatory compliance and workplace testing programs. Forensic Applications hold 15%, driven by advancements in crime scene analysis and forensic labs. Others account for 30%, covering research, biotechnology, and emerging molecular testing applications.

By End User

Hospitals lead with 30% share, reflecting adoption of in-house diagnostic capabilities. Diagnostic Laboratories hold 25%, benefiting from outsourcing trends and specialized testing. Academic & Research Institutes represent 20%, driven by research and development activities. Others account for 25%, including pharmaceutical companies, biotechnology firms, and government research facilities.

By Region

North America dominates with 30% share, due to advanced healthcare infrastructure, research funding, and high adoption of diagnostics. Europe follows at 25%, supported by established life sciences research and laboratory networks. Asia Pacific accounts for 20%, driven by emerging healthcare markets, increasing lab infrastructure, and government initiatives. Latin America represents 15%, while Middle East & Africa hold 10%, fueled by growing healthcare investments and diagnostic adoption.

Outlook & Opportunity Analysis (2024-2031)

The Life Sciences and Diagnostics Market is expected to witness robust growth, driven by increasing prevalence of chronic diseases, rising demand for personalized medicine, technological advancements in antibodies and kits, and expansion of diagnostic infrastructure in emerging markets. Key opportunities lie in Asia Pacific and Latin America, adoption of automated equipment, and next-generation reagents and molecular diagnostics.

FAQ

What is the current size of the Immunohistochemistry Market?

A: In 2022, the Immunohistochemistry Market was valued at US$ 2,302.79 million, reflecting its strong industry presence.

Q2: How large is the Immunohistochemistry Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Immunohistochemistry Market will grow to around US$4,240.65 million, demonstrating significant expansion.

Q3: What is the growth rate of the Immunohistochemistry Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.